tag:blogger.com,1999:blog-7857054149675424609.post6408556738934579759..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: MC3 Authorship Discrepancies Increase Suspicions of Cover-UpDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger8125tag:blogger.com,1999:blog-7857054149675424609.post-641590077051867102012-08-13T20:39:41.618+00:002012-08-13T20:39:41.618+00:00To anonymous:
it seems to me that you got it wron...To anonymous:<br /><br />it seems to me that you got it wrong - Dirk is not arguing that KC2 and MC3 are almost the same lipids. Indeed, there chemical structures are of course different. <br />Dirk's argumentation is this - as far as I understood: <br /><br />(1) Patents<br />- Alnylam & Tekmira filed joined patent application PCT/US2008/088676 (Dec. 2008), subject: DLin-KC-1-DMA and a Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-82166335180662864572012-08-13T05:01:37.037+00:002012-08-13T05:01:37.037+00:00Dirk,
Love the blog, but on this one I simply disa...Dirk,<br />Love the blog, but on this one I simply disagree with you. Alnylam's MC3 is not like Tekmira's KC2. KC2 is an acetal which metabolizes to a ketone. MC3is an ester that metabolizes to an alcohol. Their structures, routes of metabolism, shelf-lives, PK, potencies - are all different. Alnylam will have no problem whatsoever defending MC3 as their intellectual property.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-26440671896769521702012-07-31T07:07:13.417+00:002012-07-31T07:07:13.417+00:00Thanks V. for your comments. Can you elaborate on...Thanks V. for your comments. Can you elaborate on two issues though that relate to the timing and therefore whether this work happened/was initiated in Tekmira or not:<br /><br />1) You say this was a 'comprehensive MedChem approach', yet the MC3 provisional was filed just about half a year after ex-Tekmira people left the company;<br /><br />2)You state that this approach discovered KC2Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-34236152043577125392012-07-30T21:11:34.301+00:002012-07-30T21:11:34.301+00:00Dirk,
Because there are no comments regarding th...Dirk, <br /><br />Because there are no comments regarding the “MC3 lipid paper” and the scientific content of it, here are some personal thoughts:<br /><br />"Maximizing the Potency of siRNA Lipid..." is far away from being a poor copy of Semple's 2010 "Rational design of cationic Lipids...". No doubt, Semple's paper was a real highlight with respect to lipid chemistryAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-55236382688719579992012-07-30T19:28:02.952+00:002012-07-30T19:28:02.952+00:00Your question is too broad though to answer it in ...Your question is too broad though to answer it in this context. There are a few delivery techs that I consider interesting for gene knockdown in various tissues. Some of those that I consider of clinical or near-clinical maturity I have listed in my recent review on the 'Business of RNAi Therapeutics in 2012'.Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-72760294462299483672012-07-30T14:26:10.208+00:002012-07-30T14:26:10.208+00:00Dirk - given the recent clinical results demonstra...Dirk - given the recent clinical results demonstrating potent target mRNA knockdown in the liver via SNALP, have there been any recent developments in terms of SNALP or other RNAi delivery technologies demonstrating potent knockdown in extra-hepatic tissues (i.e., nonhuman primate and/or clinical data)?<br /><br />Thanks for your continued insights on what is going on in the field.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-32342970359851143332012-07-24T17:30:28.706+00:002012-07-24T17:30:28.706+00:00Well, they have started the Ebola trial this year ...Well, they have started the Ebola trial this year and they are about to finish the phase I PLK1 cancer study. Beyond that there appears to be work on basic delivery (lipids, aerosolation, lyophilization). Overall, of course, efforts have gone down due to cost constraints as the Alnylam situation has cost them lots in legal fees and not allowed them to close the normal type of biopharm Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-71069837794676819602012-07-24T07:11:14.130+00:002012-07-24T07:11:14.130+00:00Any comments on the progress Tekmira has made in t...Any comments on the progress Tekmira has made in their LNP efforts since the AlCana scientists were fired? It seems like pipeline and scientific progress at TKM has stalled since that unfortunate incident. The only press releases out of TKM these days seem to be about litigation or piggy backing on Alnylam's clinical results.Anonymousnoreply@blogger.com